|
BP13069
|
Brodimoprim
|
|
|
|
|
Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.
|
|
BP13070
|
5-BrdU
|
|
|
|
|
Bromodeoxyuridine (BrdU), a nucleoside analog, are used in the detection of proliferating cells and competes with thymidine for incorporation into DNA.
|
|
BP13071
|
Bromosporine
|
|
|
|
|
Bromosporine is a broad spectrum inhibitor for bromodomains for BRD2/4/9 and CECR2 (IC50: 0.41/0.29/0.122/0.017 μM), respectively.
|
|
BP13072
|
BS-181 hydrochloride
|
|
|
|
|
BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.
|
|
BP13073
|
BS194
|
|
|
|
|
BS194 is as a potent cyclin-dependent protein kinases (CDKs) inhibitor.
|
|
BP13074
|
BSJ-03-123
|
|
|
|
|
BSJ-03-123 is a potent, CDK6-selective small-molecule degrader.
|
|
BP13075
|
BSJ-4-116
|
|
|
|
|
BSJ-4-116 is a highly potent and selective CDK12 degrader (PROTAC) with an IC50 of 6 nM. It downregulates DDR genes through a premature termination of transcription, primarily through increasing poly(adenylation).
|
|
BP13076
|
Buddlejasaponin IV
|
|
|
|
|
Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation.
|
|
BP13077
|
BUR1
|
|
|
|
|
BUR1 is a Saccharomyces cerevisiae cyclin-dependent kinase (CDK) and is homologous to mammalian Cdk9, which functions in transcriptional elongation.
|
|
BP13078
|
Butyrolactone I
|
|
|
|
|
Butyrolactone I is an ATP-competitive inhibitor of CDK and cdc2 kinase family. Butyrolactone I shows antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines.
|
|
BP13079
|
BVDV-IN-1
|
|
|
|
|
BVDV-IN-1 is a non-nucleoside inhibitor (NNI) of bovine viral diarrhea virus (BVDV), with an EC50 of 1.8 μM. It directly binds to a hydrophobic pocket of the BVDV RdRp. It has antiviral activity against BVDV resistant to NNI thiosemicarbazone (TSC).
|
|
BP13080
|
C527
|
|
|
|
|
C527 is a is a pan DUB enzyme inhibitor. Which has a high potency for the USP1/UAF1 complex (IC50=0.88 μM).
|
|
BP13081
|
Ca2+ channel agonist 1
|
|
|
|
|
Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2 (EC50s: 14.23 μM and 3.34 μM) and is used as a potential treatment for motor nerve terminal dysfunction.
|
|
BP13082
|
Levoleucovorin Calcium
|
|
|
|
|
Calcium Levofolinate, a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant.
|
|
BP13083
|
Calcium N5-methyltetrahydrofolate
|
|
|
|
|
Calcium N5-methyltetrahydrofolate is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers
|
|
BP13084
|
Camostat mesylate
|
|
|
|
|
Camostat is a trypsin-like protease inhibitor and inhibits airway epithelial sodium channel (ENaC) function.
|
|
BP13085
|
CAN508
|
|
|
|
|
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. It is also a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively.CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.
|
|
BP13086
|
Caracemide
|
|
|
|
|
Caracemide inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide can be used in anticancer studies.
|
|
BP13087
|
Carmofur
|
|
|
|
|
Carmofur is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. Carmofur has been known to induce leukoencephalopathy.
|
|
BP13088
|
CASIN
|
|
|
|
|
CASIN is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
|
